<DOC>
	<DOCNO>NCT01465958</DOCNO>
	<brief_summary>The purpose open-label study evaluate pharmacokinetics , safety , tolerability subcutaneously ( SC ; skin ) administer GAMUNEX-C compare intravenously ( IV ; vein ) administer GAMUNEX-C subject 2-16 year age Primary Immunodeficiency .</brief_summary>
	<brief_title>Pharmacokinetics , Safety , Tolerability Subcutaneous GAMUNEX-C Pediatric Subjects With Primary Immunodeficiency</brief_title>
	<detailed_description>This study multi-center , open-label , single-sequence , crossover study evaluate pharmacokinetics ( PK ) , safety tolerability SC-administered GAMUNEX-C pediatric PI subject ( age 2-16 ) . The study consist Screening Phase , Run-in Phase , two treatment phase ( IV Phase SC Phase ) , End Study/Early Termination ( EOS/ET ) visit . Run-in phase : 3 - 4 month , IV Phase : ~ 4 - 5 week , SC Phase : 12 week , End Study/Early Termination ( EOS/ET ) visit : one week SC Week # 12 .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Aged 216 year old , inclusive . Documented confirm preexist diagnosis PI feature hypogammaglobulinemia require immunoglobulin replacement . Currently IgG replacement therapy serum IgG trough concentration ≥ 500 mg/dL Screening Visit . Adequate normal skin allow SC infusion . Signs assent form , applicable ( per Institutional Review Board [ IRB ] requirement ) . Parent legal guardian must sign informed consent form . Females childbearing potential must negative urine pregnancy test result must practice effective form contraception ( may include abstinence ) . History anaphylaxis severe systemic response immunoglobulin blood product . History blister skin disease , clinically significant thrombocytopenia , bleed disorder , recurrent skin infection disorder subcutaneous therapy could contraindicate . Has specific antibody deficiency disorder , IgG subclass deficiency , transient hypogammaglobulinemia infancy . History severe adverse reaction parenteral product contain immunoglobulin A ( IgA ) . Significant proteinuria and/or history acute renal failure and/or severe renal impairment ( serum creatinine 2.5 time upper limit normal [ ULN ] age gender ) and/or dialysis . Known substance prescription drug abuse past 12 month . Acquired medical condition know cause secondary immune deficiency . Receiving follow medication : systemic corticosteroid ( long term daily , &gt; 1 mg prednisone equivalent/kg/day &gt; 30 day ) ( intermittent course would exclude subject ) ; immunosuppressant ( i.e. , antimetabolites systemic calcineurin inhibitor ; NOTE : inhaled steroid allow ) ; immunomodulators . Noncontrolled arterial hypertension level ≥ 90th percentile blood pressure ( either systolic diastolic ) age height ( base http : //www.nhlbi.nih.gov/guidelines/hypertension/child_tbl.pdf ) . History current diagnosis thrombotic episode ; venous thrombus occur association medical device &gt; 2 year prior screen allow . Currently receive anticoagulation therapy . History Kawasaki disease . Participated another clinical trial involve exposure investigational product device within 30 day prior screen ( image study without investigative treatment permit ) receive investigational blood product within previous 3 month . Unable unwilling comply aspect protocol , include blood sample completion Infusion Site Reactions page SC Infusion Diary . In opinion Investigator subject may compliance problem protocol procedure protocol . Pregnant lactating . Clinical evidence significant acute chronic disease , opinion Investigator , may interfere successful completion study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>